On the stock market since 2020, it operates in the world of health and science. It has 168 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades below its recent peak — about 15% off the top. A pullback, not a collapse.
There is $599.3M in the vault; even if every debt were paid off, $599.2M would remain.
Over the last 12 months, company executives reported 62 buys and 48 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $579 — 90% above today’s price.
A loss of $303.3M against $0 in annual sales. And on top of that, sales fell from the year before.
This stock swings about 2.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts about 2 years. After that, the company needs to find new money.
On our five-subject report card, PRAX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: PRAX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (52/100) says the stock isn’t cheap.